Professional
Added to YB: 2026-04-01
Pitch date: 2026-01-17
LLY [neutral]
Eli Lilly and Company
-10.39%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$785.9B
Pitch Price
$1.0K
Price Target
N/A
Dividend
0.79%
EV/EBITDA
25.77
P/E
38.27
EV/Sales
12.62
Sector
Pharmaceuticals
Category
growth
Bristol Gate US Equity Strategy Portfolio Holding: Eli Lilly and Company
LLY (holding update): Q3 beat on GLP-1 franchise (Mounjaro/Zepbound). Now 58% US incretin mkt share, 71% new Rxs signal further gains. Mgmt raised 2025 guide 3rd time. Oral GLP-1 orforglipron launching Spring 2026 expected to expand mkt globally via ease of use, simpler supply chain, lower cost vs injectables.
Read full article (1 min)